Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The provided AI claim accurately reflects the label’s warnings about dose/concentration-related QTc prolongation, risk of torsade de pointes and serious events, contraindicated/avoided patient populations (congenital/acquired QT prolongation and uncorrected hypokalemia/hypomagnesemia), and the need to avoid QT-prolonging drugs and strong CYP3A4 inhibitors (with related ECG/monitoring concepts).
Category Scores
Accurate Statements
Toremifene prolongs QTc in a dose- and concentration-related manner.
Boxed Warning / QT Prolongation; Section 5.1; Section 12.2
QT prolongation can result in torsade de pointes, which may result in syncope, seizure, and/or death.
Section 5.1 (Prolongation of the QT Interval)
Toremifene should not be prescribed to patients with congenital/acquired QT prolongation (long QT syndrome) or uncorrected hypokalemia or uncorrected hypomagnesemia.
Boxed Warning / QT Prolongation; Section 4.2; Section 5.1
QT-prolonging drugs should be avoided with toremifene (and administration with QT-prolonging agents should be avoided).
Boxed Warning / QT Prolongation; Section 5.1; Section 7.2
Strong CYP3A4 inhibitors should be avoided with toremifene.
Boxed Warning / QT Prolongation; Section 5.1; Section 7.4
Unsupported Statements
Contradictions
Important Omissions
The label includes additional management details for scenarios where QT-prolonging agents or strong CYP3A4 inhibitors cannot be avoided (e.g., interruption of FARESTON and/or close monitoring with ECGs in patients at increased risk). The AI claim states avoidance but does not mention these contingency/monitoring instructions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claim aligns with label-recommended avoidance of contraindicated patients and avoidance of QT-prolonging drugs/strong CYP3A4 inhibitors. Omitted details relate to contingency management rather than directly contradicting the label.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omission of label contingency guidance (interrupt therapy/close ECG monitoring when co-therapy cannot be avoided).
Suggested Improvement
Add that if QT-prolonging agents or strong CYP3A4 inhibitors are required and interruption is not possible, the label recommends close monitoring for QT prolongation and ECGs in patients at increased risk.